Obesity Drug Approvals Foretell A Less Cautious FDA

Law360, New York (July 19, 2012, 9:23 PM EDT) -- The U.S. Food and Drug Administration's approval of two weight-loss drugs in less than a month — 13 years after the last such approval — signals that the FDA is willing to tolerate more risk, after years of what industry critics say was an over-cautious approach that kept good drugs off the market.

On Tuesday, the FDA approved Vivus Inc.'s Qsymia, about three weeks after approving Belviq, a drug made by Arena Pharmaceuticals GmbH. Both drugs, which work in different ways to suppress hunger, are approved...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.